MODAG Alternatives & Competitors
12 companies similar to MODAG — Neuroscience Solutions
Companies similar to MODAG
Kineta (Reverse Merger With Yumanity Therapeutics)
Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfo...
Asceneuron SA
Targeting the root cause of neurodegeneration
Spinogenix, Inc.
Developing a new class of therapeutics for neurodegenerative and psychiatric diseases
Accure Therapeutics
R&D pharma dedicated to developing innovative medicines to treat patients suffering from C...
Rival Readout
Competing with MODAG? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Cognition Therapeutics, Inc.
Advancing Accessible Solutions for Complex Neurodegenerative Diseases
CuraSen Therapeutics, Inc.
Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN
Proclara Biosciences
Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggre...
Rectify Pharma
Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein f...
BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift...
PRAEVENTIX LLC
Pioneering the future of healthcare by developing innovative therapies for bowel, dermatol...
Ophidion
Advancing brain-targeted therapies with precision and innovation for neurodegenerative and...
Caraway Therapeutics, Inc.
a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Precision Medicines for CNS a...
About MODAG
MODAG, founded in 2013, is a trailblazing biotechnology firm headquartered in Germany, prominently known for its focus on Neuroscience Solutions. The company specializes in the research and development of cutting-edge therapeutics and diagnostics for neurodegenerative diseases. It operates from the Hochtechnologiepark...
Development of therapeutics for neurodegenerative diseases, Innovative diagnostics for early detection, Clinical trials management, Research and development of oligomer modulators
Patients with Parkinson's Disease, Patients with Multiple System Atrophy, Healthcare professionals in neurology, Pharmaceutical companies
Neurodegenerative Diseases, Therapeutics Development, Diagnostics Innovation, Synucleinopathies, Multiple System Atrophy, Parkinson's Disease, Disease-modifying Therapies, Early Diagnosis, Oligomer Modulator, Small Molecule Therapeutics, Clinical Research, Patented Active Compounds, Interdisciplinary R&D, Clinical Proof-of-concept
B2B, B2B2C
Licensing, Product Sales, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around MODAG: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at MODAG on 14 May 2026. The 12 companies listed here were last checked between 26 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.